ROE của cổ phiếu CPIX là bao nhiêu?

Cumberland Pharmaceuticals Inc có tỷ suất lợi nhuận trên vốn chủ sở hữu (ROE) -33.42%.

Tỷ suất cổ tức của CPIX là bao nhiêu?

Cumberland Pharmaceuticals Inc có tỷ suất cổ tức 0.00%.

Điểm chất lượng (Quality Score) của CPIX là bao nhiêu?

AI của chúng tôi đánh giá chất lượng tài chính tổng thể của CPIX ở mức 46/100, dựa trên khả năng sinh lời, tăng trưởng, nợ và độ ổn định lợi nhuận.

Bây giờ có nên mua cổ phiếu CPIX không?

Điểm AI Timing của CPIX là 87/100, thể hiện mức độ hấp dẫn tương đối của giá hiện tại theo tín hiệu kỹ thuật và momentum — nên cân nhắc cùng điểm chất lượng và kế hoạch đầu tư của bạn.

Cổ phiếu CPIX thuộc ngành nào?

Cumberland Pharmaceuticals Inc được xếp vào ngành Healthcare >> Drug Manufacturers - Specialty & Generic trên sàn NASDAQ

Cổ phiếu CPIX (NASDAQ) | CUMBERLAND PHARMACEUTICALS INC

Stock Check Daily update data at 8:30 AM
(Price: 2026-08-05 | FS: 2026-03-31)

CPIX AI Analysis Summary

Our AI summary for CPIX: Cumberland Pharmaceuticals Inc (NASDAQ), Healthcare >> Drug Manufacturers - Specialty & Generic sector. The stock currently trades at a P/E of 0.00, ROE of -33.42%, a dividend yield of 0.00%. Its financial Quality Score stands at 46/100 — fundamentals below the market average. The AI Timing Score is 87/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

CPIX

Cumberland Pharmaceuticals Inc

USD 7.55

-0.22 (-2.83%) Day Change

Watchlist Portfolio Compare Chart

0.26

D/E

-33.4%

ROE

-10.2%

ROA

0.00%

Div Yield

CUMBERLAND PHARMACEUTICALS INC
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 7.55 Price -0.22 (-2.83%) Day Change	NEWS SCORE: 89

CPIX Chất lượng tổng thể của cố phiếu Không tốt ( Chất lượng = 46) nhưng Thời điểm mua ...(Sign In to See)...

Loading chart...

46 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: Tỷ lệ ROE tương đối thấp
Tỷ lệ ROA tương đối thấp
Lịch sử ROE tương đối thấp
ROE đang giảm đáng kể
Tăng trưởng ROA hiện tại đang dưới mức tiêu chí của chúng tôi.
Biên lợi nhuận ròng tương đối thấp.
Lịch sử Biên lợi nhuận ròng tương đối thấp.

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

Chi tiết hơn, sẽ thấy rằng các yếu tố chất lượng Không tốt , Sức khỏe tài chính Không tốt , và khả năng kiếm lợi nhuận Khá , ...

Yếu tố Chất lượng

45%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	89
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	7.55
PBV / Sector	5.46 / 10.19
Earning Per Share	-0.47

PE / Sector	N/A / 31.74
PEG or PE/Growth / Sector	N/A / -0.02
Average 1M Daily Value	1.10 M GREAT
Average 1W Daily Value	1.36 M GREAT

Yếu tố Kỹ thuật

85%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Sức khỏe tài chính

45%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Khả năng kiếm lợi nhuận

64%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	-17.24 / 12.63
NPM Average (%) / Sector	-13.97 / -10.74
NPM Change Average (%) / Sector	33.86 / 114.91 GREAT
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-10.19 / 7.67
ROA Average (%) / Sector	-7.22 / 2.97
ROA Change Average (%) / Sector	39.68 / 112.43 GREAT
ROE (%) / Sector	-33.42 / 25.75
ROE Average (%) / Sector	-21.95 / 14.00
ROE Change Average (%) / Sector	51.30 / 378.64 GREAT
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Lợi tức cho nhà đầu tư

Dividend (%) / Sector	N/A / 0.52
Dividend Average (%) / Sector	N/A / 3.06
Dividend Change Average (%) / Sector	N/A / 13.74

Chi tiết đăng ký

Analyze Date	2026-08-06 07:59:49
Symbol	CPIX
Name	CUMBERLAND PHARMACEUTICALS INC
Sector	Healthcare >> Drug Manufacturers - Specialty & Generic
Market	NASDAQ
Listed Shares	14.98 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	116.42 / 10,556.24

Tin tức, Dự báo ước tính

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 1600 West End Avenue, Nashville, TN, United States, 37203

Phone: 615 255 0068

Website: https://www.cumberlandpharma.com

Employees: 93

Sector: Healthcare >> Drug Manufacturers - Specialty & Generic

Description: Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Sancuso, a transdermal patch for the prevention of nausea and vomiting in patients receiving chemotherapy treatment; Vaprisol, an injection to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; Vibativ, an injection for the treatment of certain bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections; and Tacilia, an oral capsule for the treatment of H. pylori infection. It also develops ifetroban, a product candidate that has completed Phase II clinical trials for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy, hepatorenal syndrome, portal hypertension, aspirin-exacerbated respiratory disease, systemic sclerosis, and idiopathic pulmonary fibrosis. It serves hospital acute care, gastroenterology, and oncology markets in the United States, China, South Korea, Russia, Mexico, Australia, and Saudi Arabia. The company has a strategic alliance agreement with WinHealth Pharma Group Co. Limited. Cumberland Pharmaceuticals Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.